The DOI matches its Crossref record.
von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation
Abstract
Before de novo synthesized von Willebrand factor (vWF) leaves the endothelial cell, it undergoes endoproteolytic cleavage of its propeptide (vW antigen II). The processed vWF and propeptide are either released constitutively or, following activation of the endothelium, released through the regulated pathway. In a recent study (Borchiellini et al, Blood 88:2951, 1996), we showed that the half-life of mature vWF and of its propeptide differ fourfold to fivefold. We postulated that the molar ratio of the propeptide to mature vWF could serve as a tool to assess the extent of endothelial cell activation under physiologic and clinical conditions. To test this hypothesis, we measured mature vWF and propeptide in patients with documented acute and chronic vascular disease, including patients with thrombotic thrombocytopenic purpura (TTP), acute septicemia, and diabetes mellitus. These data were compared with experimental conditions in healthy subjects in which perturbation of the endothelium was simulated by physical exercise or by administration of 1-deamino-8-D-arginine vasopressin (DDAVP) or endotoxin. In all individuals of the latter study group, both vWF and propeptide levels were elevated during the acute phase of the experimentally induced vascular perturbation; at later time points after stimulation, only vWF levels remained elevated. In patients with sepsis and TTP, both vWF and propeptide were elevated several-fold. Thus, this pattern can readily be explained in terms of acute perturbation of the endothelium. In contrast, in patients with diabetes mellitus propeptide levels were only slightly elevated, whereas vWF levels were elevated twofold to threefold. This pattern is a typical feature of chronic, low-grade activation of the endothelium. These observations support our hypothesis that measurement of both propeptide and vWF levels allows to discriminate between chronic and acute phases of endothelial cell activation in vivo. Measurement of only vWF is less indicative in this respect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lisman, T., Bongers, T. N., Adelmeijer, J., Janssen, H. L. A., de Maat, M. P. M., de Groot, P. G., & Leebeek, F. W. G. (2006) · Hepatology · doi:10.1002/hep.21231 · Cited by 605
Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells
Rondaij, M. G., Bierings, R., Kragt, A., van Mourik, J. A., & Voorberg, J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209501.56852.6c · Cited by 344
Self-citationvon Willebrand factor, endothelial dysfunction, and cardiovascular disease
VISCHER, U. M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01949.x · Cited by 343
Inflammatory Markers, Adiponectin, and Risk of Type 2 Diabetes in the Pima Indian
Krakoff, J., Funahashi, T., Stehouwer, C. D. A., Schalkwijk, C. G., Tanaka, S., Matsuzawa, Y., Kobes, S., Tataranni, P. A., Hanson, R. L., Knowler, W. C., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1745 · Cited by 334
The endothelium in sepsis: Source of and a target for inflammation
Hack, C. E., & Zeerleder, S. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00011 · Cited by 295
Metadata
- Authors
- van Mourik, J. A., Boertjes, R., Huisveld, I. A., Fijnvandraat, K., Pajkrt, D., van Genderen, P. J. J., & Fijnheer, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-07-01
- Volume
- 94
- Issue
- 1
- Pages
- 179-185
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2408854760
- Cited by
- 204
- References
- 0
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation. https://app.cochat.ai/papers/10.1182/blood.v94.1.179.413k18_179_185
- The paper
- van Mourik, J. A., Boertjes, R., Huisveld, I. A., Fijnvandraat, K., Pajkrt, D., van Genderen, P. J. J., & Fijnheer, R. (1999). von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation. Blood. https://doi.org/10.1182/blood.v94.1.179.413k18_179_185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.